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Ever since the discovery of caspases as
major executioners of apoptotic cell
death, scientists have been contemplat-
ing whether caspases may be exploited
to kill tumor cells. However, caspases are
tightly regulated in many different ways.
For example, they are synthesized as
zymogens that require proteolytic pro-
cessing and/or dimerization for activa-
tion. Upstream caspases are activated
by apoptotic signaling cascades, which
in turn proteolytically activate down-
stream caspases for the actual cellular
destruction. In addition, once processed,
caspases are subject to inhibition by
endogenous inhibitors of apoptosis
(IAPs). These and other complexities of
caspase regulation make it difficult to
identify specific and effective targets that
are different between normal and tumor
cells for inducing caspase activity differ-
entially and potently.
To this rescue, X chromosome-linked
IAP (XIAP), the best studied member of
the IAP family, is differentially upregulat-
ed in many forms of human cancers,
suggesting its potential as an anticancer
target.To prevent cell death, XIAP direct-
ly binds to and inhibits the upstream cas-
pase, caspase-9, and downstream
caspases, caspase-3 and -7 (Figure 1).
By doing so, it acts as a brake on
caspase-mediated cellular destruction
Structural and biochemical studies have
shown that the linker proceeding the
BIR2 domain of XIAP directly blocks the
active sites of caspase-3 and caspase-7,
while the BIR3 domain inhibits caspase-
9 activity by sterically hindering its dimer-
ization (Liston et al., 2003).
In the report by Schimmer et al.
(2004), a caspase-3 derepression assay
was used to screen a total of eleven mix-
ture-based small molecule combinatorial
libraries for compounds that relieve
XIAP-mediated caspase-3 inhibition. At
least eight active compounds were iden-
tified from a chemical library of 89,856
unique polyphenylureas. These com-
pounds specifically reversed XIAP-
mediated inhibition of caspase-3 and
caspase-7, but not of caspase-9, and
were shown to interact with the linker-
BIR2 region of XIAP.
What was remarkable is that as sin-
gle agents, these polyphenylurea com-
pounds induced apoptosis of a broad
range of solid tumor and leukemia cell
lines in vitro, suppressed clonogenic sur-
vival of tumor cells, and were effective in
tumor xenograft models. This is the first
case in which reagents aiming to relieve
caspase inhibition induced tumor cell
death directly, in addition to their potenti-
ation of cell death by chemotherapeutic
agents and/or death-inducing cytokines.
The kinetics of killing were rapid and the
efficacy of killing compared favorably
with two currently used anticancer drugs,
etoposide and doxorubicin. In contrast,
relatively little toxicity was exerted on
normal cells.
These findings are highly significant
not only in cancer treatment, but also in
our understanding of differential caspase
regulation in tumor and normal cells. The
effectiveness of XIAP antagonists to
directly induce tumor cell death suggests
that caspases are already proteolytically
processed in tumor cells but are kept in
check by upregulated IAPs. This status
of caspase activation in tumor cells is
similar to the Drosophila cell death sys-
tem, in which caspases are active but
counterinhibited by IAPs, and relief of
IAP-mediated caspase inhibition triggers
cell death. Consistent with this analysis,
recent data showed evidence of
processed caspase-3 in tumor cell lines
and tumor tissues (Yang et al., 2003a).
For normal mammalian cells, however, it
appears that the stimulation of caspase
processing and activation by apoptotic
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Figure 1. XIAP, caspases, and XIAP antagonists
A: Domain organization of XIAP, showing the regions responsible for caspase-3/7 and caspase-
9 inhibition. 
B: Differential caspase activation status in cancer and normal cells and effects of different XIAP
antagonists, polyphenylureas, and Smac peptides.
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stimuli, either through the mitochondrial
pathway or the death receptor pathway,
is the major trigger of cell death.
Therefore, there is a fundamental dif-
ference in the state of caspase activation
between normal and tumor cells, which
was exploited for the anticancer potency
of these polyphenylurea XIAP antago-
nists. This difference may be rationalized
by considering the presence of many
more drives for caspase activation in
tumor cells in comparison with normal
cells (Figure 1).
However, this analysis does not
explain why previously designed XIAP
antagonists, which mimic the actions of
some endogenous IAP antagonists, did
not directly induce but only synergize
tumor cell death when used together
with chemotherapeutic agents (Fulda et
al., 2002;Yang et al., 2003b).There are a
number of endogenous IAP antagonists
in mammals, including Smac/DIABLO,
HtrA2/Omi, and XAF1 (Liston et al.,
2003). Because both Smac and HtrA2
contain an N-terminal IAP binding motif
for interacting with the BIR2 and BIR3
domains of XIAP, short cell permeable
Smac peptides have been designed to
relieve XIAP-mediated caspase inhibi-
tion.The Smac peptides/BIR3 interaction
sterically excludes the caspase-9/BIR3
interaction to release caspase-9. On the
other hand, the Smac peptides cannot
remove caspase-3 from the grip of XIAP
because they do not interact with the
linker region of XIAP. In the context of the
full-length Smac dimer, it is the simulta-
neous interaction with both the BIR2 and
BIR3 domains of XIAP that creates the
steric hindrance for the neighboring link-
er to release caspase-3 and -7 (Huang et
al., 2003).
So, which aspect of the polypheny-
lurea compounds makes them capable of
direct cell killing? Is it possible that the
compounds, which have higher potency
in comparison with the Smac peptides,
simply relieve more caspases from XIAP
inhibition or have a broader effect on
other IAP family members to induce sig-
nificant cell death? Is it possible that the
compounds possess other activities, in
addition to their role in antagonizing XIAP,
such as stimulating the activity of the
apoptosome in a way analogous to the
small molecule PETCM (Jiang et al.,
2003), or inhibiting more recently
described NF-κB activation by XIAP
(Hofer-Warbinek et al., 2000), or mimick-
ing the action of another endogenous IAP
antagonist XAF1 (Liston et al., 2003)?
Among various possibilities, it is per-
haps the most intellectually satisfying to
hypothesize that the differences in cell
death induction between the polypheny-
lurea compounds and Smac peptides
are due to their effects on different cas-
pases (Figure 1). While the relief of cas-
pase-3 and -7 from XIAP inhibition by the
polyphenylurea compounds acts at the
very distal end of the caspase cascade
to induce direct cell death, the relief of
caspase-9 inhibition by the Smac pep-
tides does not necessarily stimulate the
activity of downstream caspases if XIAP
is still around to inhibit them.
Furthermore, it appears that down-
stream caspase activation exerts a posi-
tive feedback for upstream caspase
activation, because caspase-9 cleavage
by caspase-3 has been shown to stimu-
late the apoptosome and caspase-9
activity (Zou et al., 2003), and the loss of
caspase-3 inhibition has been shown to
compromise the ability of XIAP to main-
tain inhibition of caspase-9 within the
apoptosome (Bratton et al., 2002).
Interestingly, a completely different
family of chemicals was identified from a
similar high-throughput in vitro casapse-
3 derepression assay (Wu et al., 2003).
In a cellular assay, these compounds
were able to synergize with death recep-
tor stimulation to bypass the apoptosis
block resulting from the loss of the pro-
apoptotic Bcl-2 family member Bax.
However, these compounds have not
been tested against a broad array of
tumor cells, and it would be important to
determine if they too can induce direct
cell death.
In any case, the current study
appears to have revealed that there is a
fundamental difference in the state of
caspase activation in tumor and normal
cells, and that relieving downstream
rather than upstream caspases from
XIAP inhibition is a preferred strategy for
effective anticancer therapy. Therefore,
removing inhibition of caspase-3 and -7
at the very distal end of the apoptotic
cascade may be aiming at an Achilles’
heel of cancers.
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